Male factor infertility accounts for ~50% of cases but receives a fraction of research funding and specialist attention

Male factors contribute to approximately half of all infertility cases, yet male infertility remains systematically underdiagnosed and underresearched. Most couples facing conception challenges are first seen by gynecologists who specialize in female reproductive health, and many regions have only one or two dedicated andrologists. Standard semen analysis, the primary diagnostic tool, has well-documented limitations in predicting actual fertility. Why it matters: because gynecologists are the first point of contact, the diagnostic workup focuses on the female partner first, so treatable male conditions (varicoceles, hormonal imbalances, infections) frequently go undetected, so couples are pushed into expensive IVF cycles ($15,000-$30,000 each) when simpler male-focused interventions might have resolved the issue, so the financial and physical burden of treatment falls disproportionately on women who undergo invasive egg retrieval and hormonal stimulation unnecessarily, so the lack of male fertility research perpetuates a cycle where diagnostic tools remain primitive and treatment options remain limited. The structural root cause is that reproductive medicine historically developed as a subspecialty of obstetrics and gynecology (a female-focused field), andrology never achieved the same institutional status or funding as reproductive endocrinology, and cultural stigma around male infertility discourages men from seeking diagnosis, meaning the demand signal for better male fertility care remains artificially suppressed.